121 related articles for article (PubMed ID: 15572423)
21. Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer.
Peehl DM; Feldman D
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):307-15. PubMed ID: 15663994
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulatory effects of BXL-01-0029, a less hypercalcemic vitamin D analogue, in human cardiomyocytes and T cells.
Sottili M; Cosmi L; Borgogni E; Sarchielli E; Maggi L; Francalanci M; Vannelli GB; Ronconi E; Adorini L; Annunziato F; Romagnani P; Serio M; Crescioli C
Exp Cell Res; 2009 Jan; 315(2):264-73. PubMed ID: 19014933
[TBL] [Abstract][Full Text] [Related]
24. Protease-activated receptor-1 upregulates fibroblast growth factor 7 in stroma of benign prostatic hyperplasia.
Wang W; Zhang X; Mize GJ; Takayama TK
Prostate; 2008 Jul; 68(10):1064-75. PubMed ID: 18386288
[TBL] [Abstract][Full Text] [Related]
25. Regulation of keratinocyte growth factor receptor and androgen receptor in epithelial cells of the human prostate.
Planz B; Wang Q; Kirley SD; Marberger M; McDougal WS
J Urol; 2001 Aug; 166(2):678-83. PubMed ID: 11458116
[TBL] [Abstract][Full Text] [Related]
26. Vitamin D receptor-dependent inhibition of mammary tumor growth by EB1089 and ultraviolet radiation in vivo.
Valrance ME; Brunet AH; Welsh J
Endocrinology; 2007 Oct; 148(10):4887-94. PubMed ID: 17628009
[TBL] [Abstract][Full Text] [Related]
27. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion.
Hedlund TE; Moffatt KA; Uskokovic MR; Miller GJ
Clin Cancer Res; 1997 Aug; 3(8):1331-8. PubMed ID: 9815816
[TBL] [Abstract][Full Text] [Related]
28. Expression and cellular localization of keratinocyte growth factor and its receptor in human hyperplastic prostate tissue.
De Bellis A; Crescioli C; Grappone C; Milani S; Ghiandi P; Forti G; Serio M
J Clin Endocrinol Metab; 1998 Jun; 83(6):2186-91. PubMed ID: 9626158
[TBL] [Abstract][Full Text] [Related]
29. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
30. Regulation of androgen and vitamin d receptors by 1,25-dihydroxyvitamin D3 in human prostate epithelial and stromal cells.
Leman ES; DeMiguel F; Gao AC; Getzenberg RH
J Urol; 2003 Jul; 170(1):235-40. PubMed ID: 12796696
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE.
Sepulveda VA; Weigel NL; Falzon M
Steroids; 2006 Feb; 71(2):102-15. PubMed ID: 16243370
[TBL] [Abstract][Full Text] [Related]
32. Vitamin D and prostate cancer.
Feldman D; Skowronski RJ; Peehl DM
Adv Exp Med Biol; 1995; 375():53-63. PubMed ID: 7645428
[TBL] [Abstract][Full Text] [Related]
33. The GnRH Antagonist Degarelix Directly Inhibits Benign Prostate Hyperplasia Cell Growth.
Sakai M; Elhilali M; Papadopoulos V
Horm Metab Res; 2015 Nov; 47(12):925-31. PubMed ID: 26197852
[TBL] [Abstract][Full Text] [Related]
34. A novel nonsecosteroidal VDR agonist (CH5036249) exhibits efficacy in a spontaneous benign prostatic hyperplasia beagle model.
Taniguchi K; Katagiri K; Kashiwagi H; Harada S; Sugimoto Y; Shimizu Y; Arakawa H; Ito T; Yamazaki M; Watanabe T; Kato A; Hoshino E; Takahashi T; Esaki T; Suzuki M; Takeda S; Ichikawa F; Harada A; Sekiguchi N; Ishigai M; Kawata H; Yoneya T; Onuma E; Sudoh M; Aoki Y
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):204-7. PubMed ID: 20304062
[TBL] [Abstract][Full Text] [Related]
35. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J
Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
[TBL] [Abstract][Full Text] [Related]
36. Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells.
Bonaccorsi L; Marchiani S; Ferruzzi P; Muratori M; Crescioli C; Forti G; Maggi M; Baldi E
Steroids; 2006 Apr; 71(4):304-9. PubMed ID: 16289173
[TBL] [Abstract][Full Text] [Related]
37. Androgen and prostatic stroma.
Niu YJ; Ma TX; Zhang J; Xu Y; Han RF; Sun G
Asian J Androl; 2003 Mar; 5(1):19-26. PubMed ID: 12646998
[TBL] [Abstract][Full Text] [Related]
38. Mechanistic studies to evaluate the enhanced antiproliferation of human keratinocytes by 1alpha,25-dihydroxyvitamin D(3)-3-bromoacetate, a covalent modifier of vitamin D receptor, compared to 1alpha,25-dihydroxyvitamin D(3).
Chen ML; Ray S; Swamy N; Holick MF; Ray R
Arch Biochem Biophys; 1999 Oct; 370(1):34-44. PubMed ID: 10496974
[TBL] [Abstract][Full Text] [Related]
39. Insulin-like growth factor binding protein-5 interacts with the vitamin D receptor and modulates the vitamin D response in osteoblasts.
Schedlich LJ; Muthukaruppan A; O'Han MK; Baxter RC
Mol Endocrinol; 2007 Oct; 21(10):2378-90. PubMed ID: 17595320
[TBL] [Abstract][Full Text] [Related]
40. The G gamma / T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089.
Perez-Stable CM; Schwartz GG; Farinas A; Finegold M; Binderup L; Howard GA; Roos BA
Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):555-63. PubMed ID: 12050097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
